Filter results

Clinical Studies


  • CNTO1959COR1001:A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate the Efficacy of Guselkumab in Subjects with Familial Adenomatous Polyposis Scottsdale/Phoenix, Ariz., Jacksonville, Fla. This is a proof-of-concept study to evaluate the preliminary clinical activity of guselkumab in subjects with Familial Adenomatous Polyposis. The study is designed to determine if guselkumab has clinical activity in the colorectum and duodenum, by reducing the number of polyps over a period of 24 weeks.
  • Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot Scottsdale/Phoenix, Ariz.

    The purpose of this study is to to evaluate the integration of cancer genetic testing into a mammography practice aimed toward women at intermediate- to-high lifetime risk of breast cancer. If successful, this will provide an opportunity for cancer risk stratification and individualized screening.

  • Gemini Scottsdale/Phoenix, Ariz.

    The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic Arizona cancer clinics.

  • Gemini Biorepository Scottsdale/Phoenix, Ariz.

    The purpose of this study is to develop a biorepository of blood samples  from cancer patients participating in the Gemini (IRB 19-006717) protocol. These samples will be used for future biomarker discovery and other translational studies. 

  • Precision Pharmacogenomics in Cancer Patients Scottsdale/Phoenix, Ariz.

    THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer patients in order to improve quality of life (QOL) in patients receiving clinical care at Mayo Clinic.

Contact Us for the Latest Status

Closed for Enrollment

  • Mayo Clinic Cancer Genomics Service Line Biorepository Rochester, Minn., Eau Claire, Wis., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

    The goal of the study is to create a database of clinical information and a repository of biological specimens for genetic, molecular and microbiological research to better understand hereditary cancer and help develop new therapies and preventive strategies.

  • Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis Scottsdale/Phoenix, Ariz., Rochester, Minn.

    This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.